Ontario Public Drug Programs — Executive Officer Communications

This page provides a summary of all communications, news releases, announcements, presentations, report cards, results of public consultations, recommendations from the Committee to Evaluate Drugs and funding Decisions.

This information is intended for healthcare professionals.

On this page Skip this page navigation

Overview: Executive Officer Communications

The Ontario Public Drug Programs is committed to following the principles of good drug system governance that are enshrined in the legislation by:

striving to meet the needs of Ontarians, as patients, consumers and taxpayers
involving consumers and patients in a meaningful way
operating transparently, to the extent possible, for all persons with an interest in the system, including, without being limited to, patients, health care practitioners, consumers, manufacturers, wholesalers and pharmacies
aiming to consistently achieve value-for-money and ensure the best use of resources at every level of the system
making funding decisions for drugs on the best clinical and economic evidence available, communicating those decisions openly, in as timely a manner as possible

Find the most recent communications below.

Executive Officer Communications

2024
Date	Title
December 23	Frequently Asked Questions: Glatiramer (Effective date: December 30, 2024)
December 18	Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #12 Ontario Drug Programs Reference Manual
November 22	Update: Executive Officer Notice: Ontario Naloxone Program for Pharmacies Frequently Asked Questions
November 19	Executive Officer Notice: Biosimilar November 2024 Update Questions and Answers for Pharmacies
November 12	Update: Executive Officer Notice: Funding for Minor Ailment Services in Ontario Pharmacies (Effective date: November 18, 2024) Questions and Answers for Pharmacies
October 28	*Please refer to entry posted on November 22, 2024 for the latest updated EO Notice and FAQs. Update: Executive Officer Notice: Ontario Naloxone Program for Pharmacies Frequently Asked Questions
October 15	Executive Officer Notice: Publicly Funded COVID-19 PCR Testing Services in Ontario Pharmacies Questions and Answers for Pharmacists
October 1	Memo—Test-to-Treat COVID-19 Testing Eligibility Updates for the Fall 2024-25 Respiratory Virus Season
October 7	Executive Officer Notice: Administration of COVID-19 Vaccines in Ontario Pharmacies. Frequently Asked Questions
September 30	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Executive Officer Notice: Administration of COVID-19 Vaccines in Ontario Pharmacies. Frequently Asked Questions
September 26	Executive Officer Notice: Administration of the Publicly Funded Influenza Vaccine in Ontario Pharmacies Pharmacy Questions and Answers
September 20	Executive Officer Notice: Funding of denosumab under Ontario Public Drug Programs
August 23	*Please refer to entry posted on November 22, 2024 for the latest updated EO Notice and FAQs. Update: Executive Officer Notice: to Ontario Naloxone Program for Pharmacies Question and Answers
July 29	Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #11 Ontario Drug Programs Reference Manual
July 25	*Please refer to entry posted on November 22, 2024 for the latest updated EO Notice and FAQs. Update: Executive Officer Notice: to Ontario Naloxone Program for Pharmacies Question and Answers
July 24	Executive Officer Notice: Status Update about the Funding of Direct Oral Anticoagulants (DOACs) under the Ontario Drug Benefit Program Frequently Asked Questions
July 18	Executive Officer Notice: Updated Biosimilar Policy Update: Executive Officer Notice: Biosimilar July Update (Effective date: July 31, 2024) Pharmacists FAQs – Biosimilar July Update
May 31	Frequently Asked Questions: Forteo and Teva-teriperatide (Effective date: May 31, 2024)
May 21	Executive Officer Notice: Elimination of the Facilitated Access to HIV/AIDS Products Currently Listed in Part VI-A of the Ontario Drug Benefit Formulary/CDI
May 17	Executive Officer Notice: Prescribing and Dispensing Oral Antiviral Treatments for Respiratory Viruses (Paxlovid^® and oseltamivir) Frequently Asked Questions Supplemental FAQs: Paxlovid® - Supply, pricing and testing (June 2024) Paxlovid Prescribing and Drug Interaction Information See also: Nirmatrelvir & Ritonavir (Paxlovid^®)- Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 (May 17, 2024)
May 9	Executive Officer Notice: Updated Income Eligibility Thresholds for the Seniors Co- Payment Program under the Ontario Drug Benefit Program Questions and Answers: Updated Income Eligibility Thresholds for the Seniors Co- Payment Program (SCP) under the Ontario Drug Benefit Program
May 3	Executive Officer Notice: Funding of ustekinumab under the Ontario Drug Benefit Program (Effective date: April 30, 2024) Frequently Asked Questions: Ustekinumab
April 11	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies Frequently Asked Questions
March 28	Executive Officer Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Change Mark-ups Paid to Dispensers (Effective date: April 1, 2024)
March 28	Executive Officer Notice: Amendments to Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020 (Effective date: April 1, 2024)
March 25	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies Frequently Asked Questions
March 19	*Please refer to entry posted on May 17, 2024 for the latest updated EO Notice and FAQs. Paxlovid^TM Update (Expiry dates and adjusting packages for dispensing) See also: Paxlovid™ shelf-life correction - June 14, 2023 (PDF) for lot numbers with expiry dates
March 7	Executive Officer Notice: Amendments to O. Reg. 201/96 under the Ontario Drug Benefit Act and Reg. 935 under the Drug Interchangeability and Dispensing Fee Act to modernize submission requirements for “well-established drugs.”
February 28	Executive Officer Notice: Interim Extension of the Facilitated Access to HIV/AIDS Products Currently Listed in Part VI-A of the Ontario Drug Benefit Formulary/CDI
February 9	* Please refer to entry posted on October 15, 2024 for the latest updated EO Notice. Executive Officer Notice: Publicly Funded COVID-19 PCR Testing Services in Ontario Pharmacies Questions and Answers for Pharmacists Questions and Answers for Patients
February 9	Notice: Proposed Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Change Mark-ups Paid to Dispensers
February 9	*Please refer to entry posted on November 22, 2024 for the latest updated EO Notice and FAQs. Update: Executive Officer Notice: Clarification on Ontario Naloxone Program for Pharmacies Questions and Answers
January 26	Executive Officer Notice: Update to Ozempic Listing – Change in Status to Limited Use Benefit (Effective date: January 31, 2024) Questions and Answers Regarding Ozempic Funding Status Change
January 8	Executive Officer Notice: Clarification on Restrictions to the Extemporaneous Preparations Policy
January 3	* Please refer to entry posted on November 12, 2024 for the latest updated EO Notice. Update: Executive Officer Notice: Funding for Minor Ailment Services in Ontario Pharmacies (Effective date: January 3, 2024) Questions and Answers for Pharmacies

2023
Date	Title
December 27	Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #10 Ontario Drug Programs Reference Manual
December 22	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Executive Officer Notice: Administration of COVID-19 Vaccines in Ontario Pharmacies. Frequently Asked Questions
December 15	Executive Officer Notice: Update to Biosimilar Policy (Effective date: Dec. 11, 2023) Questions and Answers for Pharmacies
December 14	Executive Officer Notice: Elimination of Facilitated Access to HIV/AIDS Drug Products from the Ontario Drug Benefit Formulary/CDI
December 12	*Please refer to entry posted on May 17, 2024 for the latest updated EO Notice and FAQs. Executive Officer Notice: Prescribing and Dispensing Oral Antiviral Treatments for Respiratory Viruses in Ontario Pharmacies Frequently Asked Questions Paxlovid Prescribing & Drug Interaction Information
November 30	Executive Officer Notice : Implementation of Renewed Three-Year Generics Initiative Between the pan-Canadian Pharmaceutical Alliance and the Canadian Generic Pharmaceutical Association
November 22	Update: Executive Officer Notice: Update to Biosimilar Policy (Effective date: Nov. 9, 2023) Questions and Answers for Pharmacies
November 17	Executive Officer Notice: Dispensing Publicly Funded Remdesivir (Veklury™) in Ontario Pharmacies Frequently Asked Questions
October 19	Proposed regulatory amendments under the Ontario Drug Benefit Act and the Drug Interchangeability and Dispensing Fee Act to modernize submission requirements for “well-established drugs.”
October 13	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Update: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccines in Ontario Pharmacies Frequently Asked Questions
October 10	Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #9 Ontario Drug Programs Reference Manual
October 10	Executive Officer Notice: Ontario Drug Benefit Program – New Online Applications and Forms
September 26	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Update: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccines in Ontario Pharmacies Frequently Asked Questions
September 25	* Please refer to entry posted on November 12, 2024 for the latest updated EO Notice. Update: Executive Officer Notice: Funding for Minor Ailment Services in Ontario Pharmacies (Effective date: October 1, 2023) Questions and Answers for Pharmacies (no change)
September 21	Executive Officer Notice: Removal of temporary PINs for Humalog^® (insulin lispro): Shortage of the insulin lispro biosimilar (Admelog^®) is resolved
September 15	* Please refer to entry posted on September 26, 2024 for the latest updated EO Notice and Pharmacy Questions and Answers. Executive Officer Notice: Administration of Publicly Funded Influenza Vaccine in Ontario Pharmacies Frequently Asked Questions
September 11	Executive Officer Notice: Changes to the Dispensing of Publicly Funded Approved Non-Prescription Drugs for Long-Term Care Home Residents
July 31	Executive Officer Notice: Dispensing Publicly Funded ranibizumab in Ontario Pharmacies (Effective date: July 31, 2023) Questions and Answers for Pharmacies
July 26	* Please refer to entry posted on November 12, 2024 for the latest updated EO Notice. Update: Executive Officer Notice: Funding for Minor Ailment Services in Ontario Pharmacies (Effective date: July 29, 2023)
July 7	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Update: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Updated July 21, 2023) Updated: Frequently Asked Questions
July 6	Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #8 Ontario Drug Programs Reference Manual
April 30	* Please refer to entry posted on November 12, 2024 for the latest updated EO Notice. Update: Executive Officer Notice: Funding for Minor Ailment Services in Ontario Pharmacies (Effective date: April 30, 2023) Questions and Answers for Pharmacies
April 24	* Please refer to entry posted on November 17, 2023 for the latest updated EO Notice. Executive Officer Notice: Dispensing Publicly Funded Remdesivir (Veklury^TM) in Ontario Pharmacies (Effective date: April 24, 2023) Questions and Answers for Pharmacies
April 21	*Please refer to entry posted on May 17, 2024 for the latest updated EO Notice and FAQs. Executive Officer Notice: Prescribing & Dispensing Publicly Funded Paxlovid in Ontario Pharmacies (No changes from December 12) Updated: Frequently Asked Questions for Pharmacies Paxlovid Prescribing & Drug Interaction Information
April 13	Executive Officer Notice: Temporary PINs for Humalog^® (insulin lispro): Shortage of the insulin lispro biosimilar (Admelog^®) (Effective date: March 31, 2023)
April 6	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies Frequently Asked Questions
April 3	Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Extend the Reconciliation Adjustment to Pharmacy Payments (Effective date: April 1, 2023)
March 31	Executive Officer Notice: Amendments to Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020 (Effective date: April 1, 2023)
March 13	Executive Officer Notice: Biosimilar Policy (Effective date: March 10, 2023) Questions and Answers for Pharmacies Patient Support Programs for Biosimilars (Effective date March 29, 2023)
March 6	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date March 6, 2023) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date March 6, 2023) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
February 28	Notice: Proposed Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Extend Reconciliation Adjustment to Pharmacy Payments
February 6	*Please refer to entry posted on May 17, 2024 for the latest updated EO Notice and FAQs. Executive Officer Notice: Prescribing & Dispensing Publicly Funded Paxlovid in Ontario Pharmacies (No changes from December 12) Updated: Frequently Asked Questions for Pharmacies
January 25	* Please refer to entry posted on October 15, 2024 for the latest updated EO Notice. Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies
January 19	Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #7 Ontario Drug Programs Reference Manuals

2022
Date	Title
December 22	* Please refer to entry posted on November 12, 2024 for the latest updated EO Notice. Executive Officer Notice: Funding for Minor Ailment Services in Ontario Pharmacies (Effective date: January 1, 2023) Questions and Answers for Pharmacies
December 21	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date December 21, 2022) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date December 21, 2022) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
December 15	* Please refer to entry posted on September 26, 2024 for the latest updated EO Notice and Pharmacy Questions and Answers. Executive Officer Notice: Administration of Publicly Funded Influenza Vaccine in Ontario Pharmacies (No change from September 20, 2022) Updated: Questions and Answers for Pharmacies
December 12	Updated: Executive Officer Notice: Supplying of Publicly Funded Evusheld™ for Pre-Exposure Prophylaxis of COVID‑19 in Ontario Pharmacies (Effective date December 12, 2022) Updated: Questions and Answers for Pharmacies
December 12	*Please refer to entry posted on May 17, 2024 for the latest updated EO Notice and FAQs. Executive Officer Notice: Prescribing & Dispensing Publicly Funded Paxlovid™ in Ontario Pharmacies (Effective date December 12, 2022) Updated: Questions and Answers for Pharmacies
December 12	Executive Officer Notice: Updated Quarterly Report Back Form for the Ontario Naloxone Program for Pharmacies (ONPP)
November 22	Executive Officer Notice: Replacement of one Mail Direct Email Service with Microsoft Office 365 Email Account Questions and Answers for Pharmacies
November 8	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date November 8, 2022) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date November 8, 2022) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
October 17	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date October 17, 2022) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date October 17, 2022) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
October 6	* Please refer to entry posted on October 15, 2024 for the latest updated EO Notice. Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies Questions and Answers for Pharmacists Questions and Answers for Patients
October 3	*Please refer to entry posted on December 12, 2022 for the updated EO Notice and Qs & As. Notice from the Executive Officer: Supplying of Publicly Funded Evusheld™ for Pre-Exposure Prophylaxis of COVID‑19 in Ontario Pharmacies Frequently Asked Questions
September 26	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date September 26, 2022) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date September 26, 2022) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
September 20	* Please refer to entry posted on September 26, 2024 for the latest updated EO Notice and Pharmacy Questions and Answers. Notice from the Executive Officer: Pharmacy administration of publicly funded influenza vaccines and claims submission using the Health Network System, 2022–2023 Frequently Asked Questions
September 12	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date September 12, 2022) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date September 12, 2022) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
September 1	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date September 1, 2022) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date September 1, 2022) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
August 22	Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #6 Ontario Drug Programs Reference Manual
August 9	* Please refer to entry posted on October 15, 2024 for the latest updated EO Notice. Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies Questions and Answers for Pharmacies Questions and Answers for Patients
August 8	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date August 8, 2022) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date August 8, 2022) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients (No change from the July 28, 2022 update)
July 28	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date July 28, 2022) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date July 28, 2022) Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
July 28	Executive Officer Notice: Policy for Methadone Maintenance Treatment Reimbursement under the Ontario Drug Benefit Program Questions and Answers for Pharmacies: Policy for Methadone Maintenance Treatment (MMT) Reimbursement under the Ontario Drug Benefit Program
July 26	*Please refer to entry posted on May 17, 2024 for the latest updated EO Notice and FAQs. Executive Officer Notice: Supplying of Publicly Funded Oral Antiviral COVID‑19 Treatment in Ontario Pharmacies (Effective date: April 12, 2022, Updated July 26, 2022) Questions and Answers for Pharmacies
July 14	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date July 14, 2022) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date July 14, 2022) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
June 24	Notice from the Executive Officer: Temporary Benefit Nutrition Products: Shortage of infant formulas for infants with food allergies and certain medical conditions
May 31	Update to the Executive Officer Notice of interim change to Extemporaneous Preparations Policy for Anti-infectives
May 13	Notice from the Executive Officer: Pan-Canadian Select Molecules Price Initiative for Generic Drugs
May 2	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date May 2, 2022) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date May 2, 2022) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
May 1	Executive Officer Notice: Update to Home Care Eligibility under the Ontario Drug Benefit Program
April 25	*Please refer to entry posted on May 17, 2024 for the latest updated EO Notice and FAQs. Executive Officer Notice: Supplying of Publicly Funded Oral Antiviral COVID‑19 Treatment in Ontario Pharmacies (Effective date: April 12, 2022, Updated April 25, 2022) Questions and Answers for Pharmacists
April 12	*Please refer to entry posted on May 17, 2024 for the latest updated EO Notice and FAQs. Executive Officer Notice: Supplying of Publicly Funded Oral Antiviral COVID‑19 Treatment in Ontario Pharmacies (Effective date: April 12, 2022) Questions and Answers for Pharmacists
April 12	* Please refer to entry posted on October 15, 2024 for the latest updated EO Notice. Updated: Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies –Eligibility
April 8	Executive Officer Notice: Providing Support for Persons with an Emergency Authorization for Humanitarian Reasons under Ontario Public Drug Programs (Effective Date: April 6, 2022)
April 7	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date April 7, 2022) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date April 7, 2022) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
April 1	Updated — Notice from the Executive Officer: Reimbursement and Claims Submission using the Health Network System relating to Drugs for Medical Assistance in Dying Updated — Frequently Asked Questions for Dispensers: Dispensing Publicly Funded Kits for Medical Assistance in Dying (MAID) and Claims Submission using the Health Network System
March 25	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date March 25, 2022) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date March 25, 2022) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
March 21	* Please refer to entry posted on October 15, 2024 for the latest updated EO Notice. Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies Questions and Answers for Pharmacists
March 17	Executive Officer Notice: Reconciliation Adjustment Percentages for 2022/23 to Improve the Value of Pharmacy Payments
March 15	Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #5 Ontario Drug Programs Reference Manual
March 7	Executive Officer Notice: Health Network System Changes to Reimbursement of Blood Glucose Test Strips
February 22	Notice from the Executive Officer: Funding of Insulin Aspart and Insulin Glargine under the Ontario Drug Benefit Program Insulin glargine Frequently Asked Questions Insulin aspart Frequently Asked Questions
February 18	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date February 18, 2022) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date February 18, 2022) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
February 18	Executive Officer Notice: Amendments to Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020 Questions and Answers for Pharmacists
February 4	* Please refer to entry posted on October 15, 2024 for the latest updated EO Notice. Updated: Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies — Eligibility
January 17	* Please refer to entry posted on October 15, 2024 for the latest updated EO Notice. Updated Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies
January 13	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date January 13, 2022) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date January 13, 2022) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
January 11	Executive Officer Notice: Updates to the Ontario Guidelines for Drug Submission and Evaluation

2021
Date	Title
December 31	* Please refer to entry posted on October 15, 2024 for the latest updated EO Notice. Updated: Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies — Eligibility
December 20	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date December 20, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date December 20, 2021) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
December 17	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date December 17, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date December 17, 2021) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
December 7	* Please refer to entry posted on September 26, 2024 for the latest updated EO Notice and Pharmacy Questions and Answers. Update: Notice from the Executive Officer: Pharmacist administration of publicly funded influenza vaccines and claims submission using the Health Network System, 2021–2022 Frequently Asked Questions
December 2	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated:Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date December 2, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date December 2, 2021) Updated: Questions and Answers for Pharmacies Updated: Questions and Answers for Patients
December 1	* Please refer to entry posted on October 15, 2024 for the latest updated EO Notice. Updated: Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies — Eligibility
November 27	* Please refer to entry posted on October 15, 2024 for the latest updated EO Notice. Updated: Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies — Eligibility
November 25	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date November 25, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date November 25, 2021) Updated: Questions and Answers for Pharmacists Updated: Questions and Answers for Patients
November 18	* Please refer to entry posted on March 21, 2022 for the latest updated EO Notice on Eligibility Updated Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies: Eligibility Criteria Questions and Answers for Pharmacists
November 17	* Please refer to entry posted on September 26, 2024 for the latest updated EO Notice and Pharmacy Questions and Answers. Update to Executive Officer Notice: Administration of the Publicly Funded Influenza Vaccines in Ontario Pharmacies — Pharmacy Technicians
November 3	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date November 3, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date November 3, 2021) Updated: Questions and Answers for Pharmacists Updated: Questions and Answers for Patients
October 27	Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #4 Ontario Drug Programs Reference Manual
October 8	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date October 8, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date October 8, 2021) Updated: Questions and Answers for Pharmacists Updated: Questions and Answers for Patients
October 8	* Please refer to entry posted on September 26, 2024 for the latest updated EO Notice and Pharmacy Questions and Answers. Notice from the Executive Officer: Pharmacist administration of publicly funded influenza vaccines and claims submission using the Health Network System, 2021–2022 Frequently Asked Questions
October 1	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date October 1, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date October 1, 2021) Updated: Questions and Answers for Pharmacists Updated: Questions and Answers for Patients
September 22	Updated Executive Officer Notice: Publicly Funded COVID‑19 Antigen Point-of-Care Testing in Ontario Pharmacies Updated Questions and Answers for Pharmacists
September 21	Executive Officer Notice: Amendments to Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020 (Effective date September 27, 2021) Frequently Asked Questions
September 8	Executive Officer Notice: Publicly Funded COVID‑19 Antigen Point-of-Care Testing in Ontario Pharmacies Questions and Answers for Pharmacists
September 8	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date September 8, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date September 8, 2021) Updated: Questions and Answers for Pharmacists Updated: Questions and Answers for Patients
September 1	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date September 1, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date September 1, 2021) Updated: Questions and Answers for Pharmacists Updated: Questions and Answers for Patients
August 27	* Please refer to entry posted on November 18 2021 for the latest updated EO Notice on Eligibility Updated Executive Officer Notice: Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria
August 18	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Eligibility (Effective date August 18, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Billing (Effective date August 18, 2021) Updated: Questions and Answers for Pharmacists Updated: Questions and Answers for Patients (FYI: No change from July 5 posting)
July 5	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Eligibility (Effective date July 5, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Billing (Effective date July 5, 2021) Updated: Questions and Answers for Pharmacists Updated: Questions and Answers for Patients
June 25	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Eligibility (Effective date June 25, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Billing (Effective date June 25, 2021) Updated: Questions and Answers for Pharmacists Updated: Questions and Answers for Patients
June 17	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Eligibility (Effective date June 17, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Billing Updated: Questions and Answers for Pharmacists Updated: Questions and Answers for Patients
June 14	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Eligibility (Effective date June 14, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Billing (Effective date June 14, 2021) Updated: Questions and Answers for Pharmacists Updated: Questions and Answers for Patients
June 14	Executive Officer Notice: Improved Access to Exceptional Access Program Drugs for Ontarians Living Near Manitoba and Quebec Borders under the Ontario Drug Benefit Program Questions and Answers
June 4	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Eligibility (Effective date June 4, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Billing (Effective date June 4, 2021) Updated: Questions and Answers for Pharmacists Updated: Questions and Answers for Patients
June 4	Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #3 Ontario Drug Programs Reference Manual
May 31	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Eligibility (Effective date May 31, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Billing (Effective date May 31, 2021) Updated: Questions and Answers for Pharmacists Updated: Questions and Answers for Patients
May 31	* Please refer to entry posted on August 27 2021 for the latest updated EO Notice on Eligibility Updated Executive Officer Notice: Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria
May 23	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Eligibility (Effective date May 23, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date May 13, 2021) (FYI: No change from May 13 posting) Updated: Questions and Answers for Pharmacists (FYI: No change from May 13 posting) Updated: Questions and Answers for Patients (FYI: No change from May 13 posting)
May 21	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Executive Officer Notice: Administration of Second Doses for Individuals who received First Dose of AstraZeneca / Covishield COVID‑19 Vaccines in Ontario Pharmacies Questions and Answers for Patients
May 18	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date May 13, 2021) (FYI: No change from May 13 posting) Updated: Questions and Answers for Pharmacists (FYI: No change from May 13 posting) Updated: Questions and Answers for Patients (FYI: No change from May 13 posting)
May 13	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date May 13, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date May 13, 2021) Updated: Questions and Answers for Pharmacists Updated: Questions and Answers for Patients
May 11	Executive Officer Notice: Pause of the Administration of First Doses of Publicly Funded AstraZeneca / Covishield COVID‑19 Vaccines in Ontario Pharmacies
May 11	Executive Officer Notice: Updated Income Eligibility Thresholds for the Seniors Co-Payment Program under the Ontario Drug Benefit Program Questions and Answers for Pharmacists Questions and Answers for Patients
May 6	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date May 6, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing Questions and Answers for Pharmacists (FYI: No change from April 30 posting) Questions and Answers for Patients (FYI: No change from April 19 posting)
May 5	Notice from the Executive Officer: Funding of enoxaparin under the Ontario Drug Benefit Program Frequently Asked Questions
April 30	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date April 30, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date April 30, 2021) Updated Questions and Answers for Pharmacists Questions and Answers for Patients (FYI: No change from April 19 posting)
April 23	* Please refer to entry posted on May 31 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers Updated Executive Officer Notice: Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria
April 19	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date April 19, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date April 19, 2021) Questions and Answers for Pharmacists Questions and Answers for Patients
April 16	Executive Officer Notice of interim change to Extemporaneous Preparations Policy for Anti-infectives for Post-Hospital Use
April 15	Executive Officer Notice: Proposed Legislative and Regulatory Amendments — Dissolution of the Citizens’ Council and the Pharmacy Council under the Ontario Drug Benefit Act
April 7	* Please refer to entry posted on April 23, 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers Updated: Executive Officer Notice: Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria
April 1	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date April 1, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date April 1, 2021) Questions and Answers for Pharmacists Questions and Answers for Patients
March 26	Executive Officer Notice: Proposal to update the Income Eligibility Thresholds for the Seniors Co-Payment Program under the Ontario Drug Benefit Program
March 25	Notice from the Executive Officer: Funding of Adalimumab under the Ontario Drug Benefit Program Frequently Asked Questions
March 22	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility (Effective date March 22, 2021) Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing (Effective date March 22, 2021) Questions and Answers for Pharmacists Questions and Answers for Patients
March 18	Notice from the Executive Officer: The Ontario Drug Programs Reference Manual, Revision #2 Notice from the Executive Officer: Regulatory Amendments relating to Recordkeeping Requirements for Pharmacies and Dispensing Physicians under the Ontario Drug Benefit Program Questions and Answers
March 16	Executive Officer Notice: Update of the OPDP At A Glance Report
March 10	* Please refer to entry posted on October 7, 2024 for the latest updated EO Notice. Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies (Effective date March 10, 2021) Questions and Answers for Pharmacists Questions and Answers for Patients
March 5	* Please refer to entry posted on April 23, 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers Updated: Executive Officer Notice: Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria
March 5	Notice from the Executive Officer: Reconciliation Adjustment Percentages for 2021/22 to Improve the Value of Pharmacy Payments
February 19	* Please refer to entry posted on April 23, 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers Executive Officer Notice: Expansion of Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies (Eligibility and Investigation Numbers) (Effective February 19, 2021) Updated Executive Officer Notice: Expansion of Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies (Billing, Pharmacy Record Documentation) (Effective February 19, 2021) Updated Questions and Answers for Pharmacists Updated Questions and Answers for Patients
January 25	Notice from the Executive Officer: Funding of Insulin Lispro under the Ontario Drug Benefit Program Questions and Answers
January 15	Executive Officer Notice: Amendments to Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020 Questions and Answers for Pharmacists

2020
Date	Title
December 18	* Please refer to entry posted on September 26, 2024 for the latest updated EO Notice and Pharmacy Questions and Answers. Executive Officer Notice: Administering the Flu Vaccine to Children Age 2 and older under the Universal Influenza Immunization Program 2020/21
December 18	Executive Officer Notice: Funding of Avsola (Infliximab) under the Ontario Drug Benefit Program Questions and Answers
December 14	Executive Officer Notice: Update to Drug Benefit Claim — Submission/Reversal Forms Questions and Answers
December 14	Executive Officer Notice: Update to Special Authorization — Allergen (SAA) Form
December 8	* Please refer to entry posted on April 23 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers ** Please refer to entry posted on February 19, 2021 for the latest updated EO Notice on Billing and Pharmacy / Patient Qs and As Executive Officer Notice: Update — Expansion of Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies (Effective December 11, 2020) Questions and Answers for Pharmacists Questions and Answers for Patients
December 7	* Please refer to entry posted on September 26, 2024 for the latest updated EO Notice and Pharmacy Questions and Answers. Executive Officer Notice: Fluarix influenza vaccine injection added to the Universal Influenza Immunization Program 2020/21 for Pharmacists Administering Flu Vaccines
November 30	* Please refer to entry posted on September 26, 2024 for the latest updated EO Notice and Pharmacy Questions and Answers. Executive Officer Notice: FluMist Nasal Spray added to the Universal Influenza Immunization Program 2020/21 for Pharmacists Administering Flu Vaccines
November 20	Executive Officer Notice: Forgery Notification Alerts in the Health Network System (HNS), including the Narcotics Monitoring System (NMS) Questions and Answers
November 5	* Please refer to entry posted on April 23 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers ** Please refer to entry posted on February 19, 2021 for the latest updated EO Notice on Billing and Pharmacy / Patient Qs and As Notice from the Executive Officer: Expansion of Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies Questions and Answers for Pharmacists Questions and Answers for Patients
October 26	Notice from the Executive Officer: Updates to Pharmacists Administering Flu Vaccine to patients without a Health card number
October 26	Notice from the Executive Officer: Reminder to pharmacies on extensions to expiry dates on Ontario health card numbers
October 22	Notice from the Executive Officer: Proposal to Streamline Recordkeeping Requirements for Pharmacies and Dispensing Physicians under the Ontario Drug Benefit Program
October 21	Executive Officer Notice: Funding of Emerade™ (Epinephrine Auto-Injector) through the Allergen Program
October 6	Executive Officer Notice: Proposal to Improve Access to Exceptional Access Program Drugs for Ontarians Living Near Manitoba and Quebec Borders
October 2	* Please refer to entry posted on September 26, 2024 for the latest updated EO Notice and Pharmacy Questions and Answers. Notice from the Executive Officer: Pharmacist administration of publicly funded influenza vaccines and claims submission using the Health Network System Frequently Asked Questions
August 24	Executive Officer Notice: Funding of Riximyo (rituximab) and Ruxience (rituximab) under the Ontario Drug Benefit Program Frequently Asked Questions
August 5	Executive Officer Notice: Funding of Allerject^® (Epinephrine Auto-Injector) through the Allergen Program
July 30	Executive Officer Notice: Inspections Return to Work
June 12	Executive Officer Notice: Removal of the 30-days’ Supply Dispensing Limit Recommendation Frequently Asked Questions
May 21	Notice from the Executive Officer: Funding of Teva UK-labelled Salamol CFC-Free (Salbutamol Sulfate) Inhaler as a Temporary Benefit on the Ontario Drug Benefit (ODB) Formulary
May 13	Notice from the Executive Officer: Regulatory Amendments to Ontario Drug Benefit Program Co-payments Frequently Asked Questions
May 13	Notice from the Executive Officer: Changes to the Trillium Drug Program in Response to COVID‑19 Frequently Asked Questions
May 1	Notice from the Executive Officer: Proposed Regulatory Amendments to Ontario Drug Benefit (ODB) Program Co-payments and Dispensing Fees
April 23	Notice from the Executive Officer: Brand Reference Price Regulations Amendment
April 23	Notice from the Executive Officer: Drug Submissions for Ontario Drug Benefit (ODB) Program during the COVID‑19 Public Health Emergency
April 15	* Please also refer to entry December 12 under 2022 for latest information on the Ontario Naloxone Program for Pharmacies (ONPP) in regards to the Quarterly Report Back Form. Executive Officer Notice: Updated Quarterly Report Back Form for the Ontario Naloxone Program for Pharmacies (ONPP) Questions and Answers for the Updated QRBF Quarterly Report Back Form
April 15	Notice: Ontario Drug Benefit Program and Exceptional Access Program Changes during the COVID‑19 Public Health Emergency
April 7	Notice from the Executive Officer: Regulation Amendments to Private Label Products and Brand Reference Pricing Rules
April 1	Notice: Extending Submission Period for Electronic Drug Claim Reversals and The Ontario Drug Programs Reference Manual, Revision #1 Frequently Asked Questions
April 1	Notice: Policy for Methadone Maintenance Treatment Reimbursement under the Ontario Drug Benefit Program Frequently Asked Questions for Pharmacists
March 30	Notice from the Executive Officer: Proposed amendments to the effective date of changes to allow Private Label Products to be funded under the Ontario Drug Benefit (ODB) Program and Designated as Interchangeable Products on the ODB Formulary
March 30	Notice from the Executive Officer: Proposed Regulatory Amendments on Rules for Determining Brand Reference Prices
March 30	Notice from the Executive Officer: Funding of Truxima (rituximab) under the Ontario Drug Benefit Program Frequently Asked Questions
March 23	Notice: Updates to the Ontario Guidelines for Drug Submission and Evaluation
March 20	Notice: Ontario Drug Benefit (ODB) Program Changes and Guidance for Dispensers during the COVID‑19 Public Health Emergency
March 2	Notice: Reconciliation Adjustment Percentages for 2020/21 to Improve the Value of Pharmacy Payments

2019
Date	Title
December 23	Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act to reduce Administrative Burden to Drug Manufacturers and Pharmacies
December 23	Notice: Updates to the Ontario Guidelines for Drug Submission and Evaluation Notice
December 16	Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act and Regulation 935 made under the Drug Interchangeability and Dispensing Fee Act to reduce restrictions on Private Label Products and Ordinary Commercial Term benefits
December 16	Notice: Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020 * Please refer to entry posted on September 21, 2021 for an amendment to the Policy effective September 27, 2021 Frequently Asked Questions Key Facts for Pharmacists Key Facts for Patients and Families Attestation Notice of Change in LTC Home Primary Pharmacy Service Provider Form
December 16	Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Improve the Value of Pharmacy Payments Frequently Asked Questions for Pharmacists
October 28	Notice: Proposal to Improve the Value of Pharmacy Payments
October 28	Notice from the Executive Officer: Proposal to Reduce Administrative Burden to Drug Manufacturers and Pharmacies
October 18	* Please refer to entry posted on September 26, 2024 for the latest updated EO Notice and Pharmacy Questions and Answers. Notice from the Executive Officer: Pharmacist administration of publicly funded influenza vaccines and claims submission using the Health Network System Frequently Asked Questions
October 1	Notice from the Executive Officer: Updates to the Drug Evaluation Process for Biosimilar Products
September 12	Notice from the Executive Officer: Funding Flash Glucose Monitoring System Through the Ontario Drug Benefit Program
July 31	Notice from the Executive Officer: Updated Funding of Erelzi (etanercept) under the Ontario Drug Benefit Program Frequently Asked Questions
July 24	Notice from the Executive Officer Submission Requirements: Flash GlucoseMonitoring (FGM)
July 4	Notice from the Executive Officer: Updates to the Ontario Guidelines for Drug Submission and Evaluation
June 4	Notice from the Executive Officer: Change to the Health Network System Subscription Agreement for Pharmacy Operators
April 26	Notice from the Executive Officer: Proposals to Establish More Efficient Pharmacy Reimbursement Policies
March 13	Notice from the Executive Officer: Buprenorphine/Naloxone (Suboxone^® and generics) Reimbursement Reminder under the Ontario Drug Benefit Program
February 27	Notice from the Executive Officer: Amendment to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to make changes to Ontario Drug Benefit Program coverage for children and youth aged 24 years and under (OHIP+) Frequently Asked Questions for Patients Frequently Asked Questions for Pharmacists
February 13	Notice from the Executive Officer: Extension of the Temporary Facilitated Access Mechanism (Rheumatology) until March 31, 2019)
February 1	Notice from the Executive Officer: Administrative Monetary Penalty Issued for Acceptance of Rebates Rebate Order
January 2	Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to make changes to Ontario Drug Benefit Program coverage for children and youth aged 24 years and under (OHIP+)

2018
Date	Title
December 31	Notice from the Executive Officer: Interim Extension of the Temporary Facilitated Access Mechanism (Rheumatology)
December 4	Notice from the Executive Officer: Completion of Strengthening Pharmacy Payment Management
October 29	Notice from the Executive Officer: Proposed Amendments to Regulations under the Ontario Drug Benefit Act and the Drug Interchangeability and Dispensing Fee Act relating to Private Label Products
October 4	* Please refer to entry posted on September 26, 2024 for the latest updated EO Notice and Pharmacy Questions and Answers. Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines and Claims Submission using the Health Network System Frequently Asked Questions
September 25	Notice from the Executive Officer: Update on Claims Submission for Valved Holding Chambers through the Ontario Drug Benefit Program
September 20	Notice from the Executive Officer: Funding of Renflexis (infliximab) under the Ontario Drug Benefit Program Frequently Asked Questions
September 20	Notice from the Executive Officer: Funding of Glatect (glatiramer acetate) under the Ontario Drug Benefit Program Frequently Asked Questions
September 10 (Updated October 11)	Notice from the Executive Officer: Availability and Funding of AUVI-Q^® (Epinephrine Auto-Injectors) as a Result of the Shortage of EpiPen^® Products
August 14	Notice from the Executive Officer: Claim Submission/Reversal and Special Authorization (Allergen) forms
July 30	Notice from the Executive Officer: Update on OHIP+
May 4	Notice from the Executive Officer: Refreshed ODB Report Card
May 1	Notice from the Executive Officer: Update Regarding Strengthening Pharmacy Payment Management
March 29 (Updated October 12)	Notice from the Executive Officer: Changes in the Way Pharmacies Verify Eligibility for Individuals Receiving Social Assistance Identification you can use to get health services How to Register Your Pharmacy for the SAV Portal SAV Portal Info Sheet
March 21 (Updated April 27)	*Please refer to entry posted on November 22, 2024 for the latest updated EO Notice and FAQs. Notice from the Executive Officer: Funding of Naloxone Nasal Spray through the ONPP and Updates to the Existing Program Frequently Asked Questions Instructional Insert
March 8	*Please refer to entry posted on November 22, 2024 for the latest updated EO Notice and FAQs. Notice from the Executive Officer: Funding of Naloxone Nasal Spray through the ONPP Frequently Asked Questions
March 5	Notice from the Executive Officer: Pan-Canadian Select Molecule Price Initiative for Generic Drugs
March 2	Notice from the Executive Officer: Ontario Drug Benefit Act Regulatory Amendment to Support the Ontario Basic Income Pilot (OBIP) Frequently Asked Questions
February 21	Notice from the Executive Officer: Funding of Hepatitis B Drugs under the Ontario Drug Benefit Program Frequently Asked Questions
February 8	Notice from the Executive Officer: Addition of Nurse Practitioners to the Palliative Care Facilitated Access (PCFA) Mechanism
January 24	Notice from the Executive Officer: Edition 43 of the Ontario Drug Benefit Formulary
January 16	Notice from the Executive Officer: Ontario Drug Benefit Act Proposed Regulatory Amendments to Align Maximum Days’ Supply of Prescriptions Dispensed for Ontario Works Recipients 25 years of Age and Older
January 10	Notice from the Executive Officer: Ontario Drug Benefit Act Proposed Regulatory Amendment to Support the Ontario Basic Income Pilot (OBIP) Frequently Asked Questions

2017
Date	Title
December 22	Notice from the Executive Officer: Drug Submission — Submission Requirements: Valved Holding Chambers (VHCs)
December 21	Notice from the Executive Officer: Funding Valved-Holding Chambers through the Ontario Drug Benefit Program
December 14	Notice from the Executive Officer: Funding of Erelzi (etanercept) under the Ontario Drug Benefit Program Frequently Asked Questions
December 14	Notice from the Executive Officer: Temporary Facilitated Access Mechanism (Rheumatology) for Ontario Drug Benefit Recipients aged 24 years and under
December 1	Notice from the Executive Officer: Removal of the Special Authorization (Allergen) Form for Pharmacy Dispensing of Epinephrine Auto-Injectors for Ontario Drug Benefit recipients
November 17	* Please refer to entry posted on September 26, 2024 for the latest updated EO Notice and Pharmacy Questions and Answers. Addendum: Notice from the Executive Officer: Addition of Agriflu^® to the Universal Influenza Immunization Program
October 13	* Please refer to entry posted on September 26, 2024 for the latest updated EO Notice and Pharmacy Questions and Answers. Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines and Claims Submission using the Health Network System for the 2017/2018 Influenza Immunization Season Frequently Asked Questions
September 21	Notice from the Executive Officer: Notice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for the Fentanyl Transdermal Patch Frequently Asked Questions
September 21	Notice from the Executive Officer: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Support the Homes for Special Care Modernization Initiative
September 1	Notice from the Executive Officer: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Strengthen Pharmacy Payment Management
September 1	Notice from the Executive Officer: Amendment to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Create and Implement OHIP+: Children and Youth Pharmacare
August 23	Notice from the Executive Officer: Notice from the Executive Officer: Thyroid (Desiccated Thyroid) Delisting
August 3	Notice from the Executive Officer: Funding of Mifepristone/Misoprostol (Mifegymiso) (updated December 7, 2017) Frequently Asked Questions for Health Care Providers (updated December 7, 2017) Frequently Asked Questions for Patients (updated December 7, 2017)
August 1	Notice from the Executive Officer: Funding of filgrastim under the Ontario Drug Benefit Program Frequently Asked Questions
July 21	Notice from the Executive Officer: Funding of Brenzys (etanercept) under the Ontario Drug Benefit Program Frequently Asked Questions
July 11	Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Create and Implement OHIP+: Children and Youth Pharmacare Program
July 7	Notice from the Executive Officer: Ontario Drug Benefit Act, Legislative amendments to recognize the role of Nurse Practitioners in requesting Exceptional Access Program products and prescribing Listed Substances (Bill 87) Frequently Asked Questions for Health Care Providers
June 29	Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Strengthen Pharmacy Payment Management
March 16	Notice from the Executive Officer: Pan-Canadian Select Molecule Price Initiative for Generic Drugs
February 21	Notice from the Executive Officer: Funding of Hepatitis C drug products under the Ontario Drug Benefit Program Frequently Asked Questions for Health Care Providers Frequently Asked Questions for Patients
January 27	Notice from the Executive Officer: Updated Reminder Regarding Delisting of High-Strength Long-Acting Opioids under the Ontario Drug Benefit (ODB) Program

2016
Date	Title
December 21	Notice from the Executive Officer: Funding of Grastofil (filgrastim) under the Ontario Drug Benefit program Frequently Asked Questions
December 1	Notice from the Executive Officer: Funding of Inflectra under the Ontario Drug Benefit Program Frequently Asked Questions
November 30	Notice from the Executive Officer: Update Regarding Palliative Care Access to High-Strength Long-Acting Opioids under the Ontario Drug Benefit (ODB) Program
October 24	* Please refer to entry posted on September 26, 2024 for the latest updated EO Notice and Pharmacy Questions and Answers. Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines for 2016–2017 Season and Claims Submission using the Health Network System Frequently Asked Questions
October 07	Notice from the Executive Officer: Application of Generic Substitution to the Exceptional Access Program Frequently Asked Questions for Patients Frequently Asked Questions for Pharmacists Frequently Asked Questions for Physicians
September 26	Notice from the Executive Officer: Regulation amendments to optimize appropriate access to unlisted, non-Formulary drug products and further streamline submission requirements for generic drug products
September 16	Notice from the Executive Officer: Regulation to support the Safeguarding our Communities Act, 2015 (Patch for Patch Return Program) Frequently Asked Questions for Prescribers and Pharmacists
September 16	Notice from the Executive Officer: Drug Submission — Ontario Guidelines for Drug Submission and Evaluation 2016
September 02	Notice from the Executive Officer: Changes in the Way Social Assistance Clients Access Drug Coverage Updated Drug Eligibility Card Pharmacy Information Sheet Updated User Guide Updated ODB Cannot be confirmed via HNS Updated ODB Cannot be confirmed via HNS — Accessible version Drug Eligibility Pharmacy Quick Reference Guide Drug Eligibility Pharmacy Questions and Answers For Social Assistance Clients Drug Eligibility Card Client Information Sheet Social Assistance Client Cheque Insert — Aug./Sept. version Social Assistance Client Cheque Insert — Oct./Nov. version
August 17 (Updated April 27)	* Please refer to entry November 22, 2024 for current information on the Ontario Naloxone Program for Pharmacies (ONPP). The materials below are available below for reference purposes. * Please also refer to entry April 15 under 2020 for new information in regards to the Quarterly Report Back Form. Notice from the Executive Officer: Reminder — Ontario Naloxone Program for Pharmacies (ONPP) Notice from the Executive Officer: Ontario Naloxone Program for Pharmacies (ONPP) Frequently Asked Questions for Pharmacists
August 15	* Please also refer to entry April 1 under 2022 for new information on the Medical Assistance in Dying Program. The materials below are available below for reference purposes. Notice from the Executive Officer: Reimbursement and Claims Submissions using the Health Network System relating to Drugs for Medical Assistance in Dying Frequently Asked Questions for Pharmacists
July 20	Notice from the Executive Officer: Changes to the Ontario Drug Benefit (ODB) Program Funding of Opioid Medications Frequently Asked Questions for Pharmacists
July 4	Notice from the Executive Officer: MedsCheck Program Enhancements
June 10	Notice from the Executive Officer: Health Network System (HNS) Changes to Support the Maximizing Quantity Dispensed for Chronic-Use Medications Initiative Frequently Asked Questions
June 1	Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act to optimize appropriate access to unlisted, non-Formulary drug products and further streamline submission requirements for generic drug products
June 1	Notice from the Executive Officer: Proposed Regulation under the Safeguarding our Communities Act (Patch for Patch Return Policy)
April 15	Notice from the Executive Officer: Regulation Amendments to Expand Access to the Seniors’ Co-Payment Program under the Ontario Drug Benefit (ODB) Program
March 22	Executive Officer Notice Drug Submission — Information Bulletin
March 15	Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs
March 11	Notice from the Executive Officer: Funding of Inflectra under the Ontario Drug Benefit Program Frequently Asked Questions
February 29	Notice from the Executive Officer:Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act to update cost-sharing arrangements for non-low income seniors under the Ontario Drug Benefit (ODB) program

2015
Date	Title
November 23	Notice from the Executive Officer: New Blood Glucose Test Strip Reimbursement Policy
November 13	Notice from the Executive Officer: Claims submission for prescriptions with drug costs over $10,000 Frequently Asked Questions
October 13	* Please refer to entry posted on September 26, 2024 for the latest updated EO Notice and Pharmacy Questions and Answers. Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2015-2016 Season and Claims Submission using the Health Network System FAQ_flu_mist_20151013.pdf">Frequently Asked Questions updated October 2015
September 18	Notice from the Executive Officer: Regulation Amendments to Streamline Submission Requirements for Certain Generic Products seeking Interchangeability Designations on the Ontario Drug Benefit Formulary
September 18	Notice from the Executive Officer: Regulation Amendments to Support Sustainability and Access for the Ontario Public Drug Programs
September 18	Notice from the Executive Officer: Supporting Sustainability and Access for the Ontario Drug Benefit Program Questions & Answers for Pharmacists Questions & Answers for Physicians Questions & Answers for Patients Chronic-use Medications List by Generic Name
July 23	Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act Questions & Answers for Patients
May 20	Notice from the Executive Officer: Tiered Generic Pricing Framework
March 10	Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs

EO listing of terminated Health Network System Accounts

The following is a list of every pharmacy operation that has had its billing privileges revoked, its right to receive payment suspended, and its Health Network System (HNS) Subscription Agreement terminated, because the Executive Officer (EO) has reasonable grounds to believe that the operator has submitted unsupported and invalid claims for payment under the Ontario Drug Benefit (ODB) Program.

Pharmacy Name	Address	Corporation	Officers/Directors/Shareholders (OCP# if applicable)	Designated Manager	Date
3M Drug Mart	7117 Bathurst Street Unit 105 Thornhill, ON	St. Abu-Seifein Drugs Ltd.	Maged (Mike) Hanna (215337) Adel Tadros (111600) Renee Samuel	Maged (Mike) Hanna (215337)	April 7, 2020
ACE Pharmacy	7-373 Steeles Avenue West Brampton, ON	J B Kothari Corporation	Bhavesh Kothari (217389)	Bhavesh Kothari (217389)	August 31, 2012
Annex Optical Pharmacy	882 Bathurst Street Toronto, ON	747054 Ontario Limited	David (Michael) Wu (89818)	David (Michael) Wu (89818)	November 9, 2012
Akop’s Pharmacy	14 Main Street Elgin, ON	Akop’s Pharmacy Inc.	Akop Shaboian (215101)	Akop Shaboian (215101)	April 11, 2017
Ayda Pharmacy	1801 Eglinton Avenue West Toronto, ON	Ayda Pharmacy Inc.	Ragaie Khalil (205504)	Ragaie Khalil (205504)	March 24, 2014
Bathurst-Dundas Pharmacy Ltd. Guardian	755-757 Dundas Street West Toronto, ON	Bathurst-Dundas Pharmacy Ltd.	Joy Abanzukwe (103497)	Joy Abanzukwe (103497)	September 2, 2008
Blossom Park Pharmacy	2928 Bank Street Ottawa, ON	Luke’s Pharmacy Inc.	Luke Skywalker (72192)	Luke Skywalker (72192)	June 14, 2021
Central Weston Pharmacy & Medical Clinic	2105 Weston Road Toronto, ON	BBH Pharmacies & Medical Services Inc.	Andrew Besada (610659) Atef Besada (106836)	Andrew Besada (610659)	July 17, 2019
Chapman’s Pharmacy	648-650 Dundas Street London, ON	2099065 Ontario Inc.	Shamez Kassam (215893) Kamaludin Kassam	Kinfe Blad (211876)	May 30, 2019
Chesswood Pharmacy	3750 Chesswood Drive, Unit 1 Toronto, ON	Chesswood Pharmacy Inc.	Chi (Eric) Lo (116076) Nestor Fernandez	Chi (Eric) Lo (116076)	January 29, 2014
College Centre Pharmacy II	528 College Street Toronto, ON	St. Meena Pharmacy Ltd.	Anhal Yacob (204896)	Anhal Yacob (204896)	March 26, 2021
Cundles Pharmacy	18 Cundles Road East Barrie, ON	Brown Wood Pharm. Inc.	Daniel Hanna (210352)	Daniel Hanna (210352)	August 1, 2017
Danforth Medical Pharmacy	1156 Danforth Avenue Toronto, ON	Wellness Drug Mart Ltd.	Magdy Salama (209088)	Magdy Salama (209088)	March 16, 2012
Dufferin Central Pharmacy	1649 Dufferin Street Toronto, ON	Dufferin Central Pharmacy Ltd.	Leon Rawa (106747) Michele Rawa	Leon Rawa (106747)	December 21, 2020
Dukh Bhanjan Pharmacy	475 Charolais Boulevard, Unit B5 Brampton, ON	2216001 Ontario Inc.	Abhaya Dixit (214669) Shady Mawad (218593)	Abhaya Dixit (214669)	February 22, 2013
Elgin Mills Crossing I.D.A. Pharmacy	3-10 John Birchall Road Richmond Hill, ON	802246 Ontario Limited	Nash Darani (79286) Nargis Darani	Nash Darani (79286)	September 22, 2016
Erie Health & Wellness Pharmacy	101 Erie Street Windsor, ON	8163219 Canada Ltd.	Abdul Baqi (214965) Nighat Nasreen Tahira Naheed	Abdul Baqi (214965)	November 4, 2014
Express Aid I.D.A. Pharmacy	15 - 477 Grove Street Barrie, ON	Express Aid Pharmacy on Grove Inc.	Nimet Lalji (200976) Sbhanji Holding Company	Nimet Lalji (200976)	January 9, 2018
Finch Medical Pharmacy	78 Finch Avenue East Toronto, ON	Wellness Drug Mart Ltd.	Magdy Salama (209088)	Magdy Salama (209088)	March 16, 2012
Guardian Drugs	1995 Finch Avenue West Toronto, ON	Pharmacia Drugs Ltd.	Diep Ngoc Tran (101052) Huucu Nguyen	Diep Ngoc Tran (101052)	September 2, 2008
Health Link Pharmacy	10555 Jane Street, Unit 8 Maple, ON	Health Link Consultants, Inc	Flora Farsad-Abarjy (215689)	Flora Farsad-Abarjy (215689)	August 10, 2012
Hi-Field Drug Mart	792 Dundas Street West Toronto, ON	Thi Pham Buu	Thi Phuong Khanh Pham Buu (103225)	Thi Phuong Khanh Pham Buu (103225)	October 22, 2009
IDA Hanin Drug Mart	682 Bloor Street West Toronto, ON	1188964 Ontario Inc.	Magdy Salama (209088) Amani Salama (216329)	Magdy Salama (209088)	August 29, 2011
IDA Rideau Medical Pharmacy	580 Rideau Street Ottawa, ON	2281079 Ontario Inc.	Waseem Shaheen (206544)	Waseem Shaheen (206544)	May 21, 2015
Island Plaza Pharmacy	1A-540 King Street West Oshawa, ON	2347032 Ontario Inc.	Jerome Kan (609493) Margaret Ting (201828)	Jerome Kan (609493)	August 9, 2021
Jennas I.D.A. Pharmacy	2-796 Burnhamthorpe Road West Mississauga, ON	802246 Ontario Limited	Nash Darani (79286) Nargis Darani	Nash Darani (79286)	September 22, 2016
Kim Pharmacy	1198 Bloor Street West Toronto, ON	1726878 Ontario Inc.	Thi Kim Tien Nguyen (205136)	Thi Kim Tien Nguyen (205136)	November 2, 2009
Lawrence Medical Pharmacy	1575 Lawrence Avenue West Toronto, ON	Son Hing Drugs Inc.	Sharon Son Hing Lawrence Son Hing (65374) Nicole Son Hing Suzanne Son Hing Elizabeth Toth (204196)	Elizabeth Toth (204196)	April 13, 2012
Leone Pharmacy	1615 Dufferin Street Toronto, ON	2269669 Ontario Limited	Laureano Leone (20745) Herman Ma (61492)	Herman Ma (61492)	August 16, 2011
Lighthouse IDA Compounding Pharmacy	130 Hollidge Boulevard Aurora, ON	Lighthouse Inc.	Jamil Rashid (205544)	Jamil Rashid (205544)	August 29, 2011
Lotus Pharmacy	81 Huron Street Toronto, ON	1554105 Ontario Ltd.	Can Minh Le (201024) Hai Le (110922)	Can Minh Le (201024)	August 21, 2008
Main Drug Mart	2558 Danforth Avenue Toronto, ON	Mina Drug Limited	Souren Agemian (922) Sherif Abdel Messih (67229) Mervat Abdel Messih(67210)	Sherif Abdel Messih (67229)	August 24, 2012
Main Drug Mart	510 Trethewey Drive Toronto, ON	A. & M. Drugs Limited	Atef Besada (106836) Souren Agemian (922)	Atef Besada (106836)	July 17, 2019
Medi-Pharm Pharmacy	2535 Major Mackenzie Drive Toronto	Peace Pharma Inc	Zafar Ahmad (212220) Naveed Ahmad (215069) Ahsan Khan (203620)	Zafar Ahmad (212220)	November 28, 2012
Metro Pharmacy	500 Sheppard Avenue East Toronto, ON	Triex International Inc.	Shohreh Torabi (204608) Hossein Ahmadian	Shohreh Torabi (204608)	July 15, 2015
MT Cross Pharmacy	503 Concession Street Hamilton, ON	Concession Medical Clinic Inc.	Ayman Mikhael (111279) Amgad George Fahim	Safaa Eskander (116661)	August 1, 2014
Mycurex Pharmacy Clinic	40 Dundas Street West Mississauga, ON	Sobhani Inc.	Muhammad Subhani (82066)	Muhammad Subhani (82066)	September 2, 2014
MD Health Pharmacy	186 Main Street South Brampton, ON	St. Maharial Pharmacy Inc.	Lilian Fam (608926) Sameh Sadek (601938)	Sameh Sadek (601938)	June 29, 2016
Neighbour’s Drug Mart	330 Steeles Avenue West, Thornhill, ON	Neighbour’s Drug Mart Ltd.	Sina Salehi (614463; current director) Galilna Pivovarov (91103; former director)	Sina Salehi (614463; current DM) Galilna Pivovarov (91103; former DM)	September 16, 2022
Nhatrang Pharmacy	673 College Street Toronto, ON	Nhatrang Pharmacy Ltd.	Ngu Van Hoa (101222)	Ngu Van Hoa (101222)	October 22, 2009
Noor Drug Mart	3-640 Eglinton Avenue West Mississauga, ON	Noor Drug Mart Inc.	Eiman Amin (202872) Galal Elsaigh	Eiman Amin (202872)	August 21, 2013
Northcliffe Pharmacy	1751 Eglinton Avenue West Toronto, ON	Northcliffe Pharmacy Limited	Sherif Gerges (205836)	Sherif Samwaiel (218729) Sandra Gerges (612561) Sherif Samwaiel (218729) Sylvia Mekhail (604292)	March 27, 2012
Oakwood Pharmacy	332 Oakwood Avenue Toronto, ON	St. Pola Drugs Inc.	Maher Boazak (212036)	Maher Boazak (212036)	May 6, 2014
Olde Walkerville Pharmacy	1701 Wyandotte Street East Windsor, ON	Olde Walkerville Pharmacy Ltd.	Bichoy Maurice (605094) Mina Michael (218353)	Dejan Buric (621776)	August 14, 2018
PARS Medical Pharmacy	10171 Yonge Street Richmond Hill, ON	Ultra Care Pharmacy Inc.	Ahmed Hassan (610688) Tamer Elokda (612346)	Tamer Mosallam (613562)	August 20, 2015
Pharm Can Drug Mart	71 Willow Street Ottawa, ON	Pharm Can International Inc.	Guo (Philip Sam) Ma (213537) Zou Pan	Guo (Philip Sam) Ma (213537)	November 23, 2017
Pharm Can Drug Mart	71 Willow Street Ottawa, ON	Hanhan Inc.	Bingyi Han (620381)	Bingyi Han (620381)	October 7, 2022
Pharmalinx Guardian Pharmacy	2101 Brimley Road, Unit 103 Toronto, ON	Pharmalinx Medical Centre Inc.	Shani-Abbas (Shani) Siwani (614754) Juma Sarfraz Murtaza Jacksi	Shani-Abbas (Shani) Siwani (614754)	November 14, 2019
Rathburn Pharmacy	592 Rathburn Road West Mississauga, ON	St. Philopateer Drugs Inc.	Said Attalla (209632)	Said Attalla (209632)	July 21, 2011
Remedy's Rx Brock Medical Pharmacy	1637 Dundas Street West Toronto, ON	2037424 Ontario Inc.	Joy Abanzukwe (103497)	Stanislava (Stanya) Louda (209276)	August 14, 2018
Rexdale Mall Pharmacy	6-2267 Islington Avenue Toronto, ON	9095357 Canada Ltd.	Abdul Wajid (215313) Muhammad Ashraf (206788) Rehana Yasmeen Khan	Abdul Wajid (215313)	July 13, 2022
Rideau Pharmacy	390 Rideau Street Ottawa, ON	1900008 Ontario Inc.	Amir Kamel (613681) John Phlamon (605411) Pierre Nasralla (208584)	Amir Kamel (613681) Mirelle (Mira) Tawdrous (618681) Ashraf Luca (621651)	August 14, 2018
Rose Pharmacy	2077 Weston Road Toronto, ON	Dong Phuong Hong Drugs Ltd.	Hong Khac Ngo (106283)	Hong Khac Ngo (106283)	June 13, 2008
Richmond Medical Pharmacy	9206 Yonge Street Richmond Hill, ON	1573548 Ontario Inc.	Joseph Salek (77224)	Atossa Babaie-Nami (212753)	August 16, 2011
Sheppard Warden Pharmacy	3410 Sheppard Avenue East Toronto, ON	St. Cyril Drugs Ltd.	Nashaat Ramzy (106801)	Nashaat Ramzy (106801)	December 7, 2011
Spadina Avenue Pharmacy	300B Spadina Avenue Toronto, ON	Spadina Avenue Pharmacy Ltd.	Olusola Alugo (211872) Tien Nguyen	Olusola Alugo (211872)	July 25, 2008
St. Laurent IDA Pharmacy	1237 Donald Street Gloucester, ON	Three Angels Pharma Inc.	Maged Ghoubrial (612453) Amir Sedrak (621781)	Amir Sedrak (621781)	November 3, 2021
Sunshine Pharmacy	1183 Weston Road Toronto, ON	Maranatha Pharmacy Group Inc.	Sami Naguib (212412)	Ovietobore (Felix) Ayigbe (204476) Ovietobore (Felix) Ayigbe (204476)	August 26, 2011
Supercare Pharmacy	2867 Jane Street Downsview, ON	Maranatha Drugs Inc.	Said Attalla (209632) Gina Ghobrial (212885)	Gina Ghobrial (212885)	July 13, 2012
Swiderski Pharmacy	1-3015 Parkerhill Road Mississauga, ON	Swiderski Pharmacy Ltd.	Richard Swiderski (112321) Joanna Swiderski (202372)	Richard Swiderski (112321)	August 18, 2017
Tamimi Pharmacy	1760 Tecumseh Road Windsor, ON	Tamimi Pharmacy Ltd.	Khalid Al-Tamimi (612849) Ahmed Al-Tamimi (215793)	Ahmed Al-Tamimi (215793)	January 9, 2012
Torbram Pharmacy	1090 Peter Robertson Boulevard Brampton, ON	2023059 Ontario Inc.	Sangita Sharma (112437) Abhay Sharma	Rita Jurkuvenas (52086)	January 18, 2018
Total Care Pharmacy	3155 Eglinton Avenue East Scarborough, ON	Mona Yacoub Drug Limited	Mona Yacoub (210496)	Nancy Wu (51632)	February 15, 2012
Total Health #110	799 Bloor Street West Toronto, ON	JSMMA Inc.	Sherif Gerges (205836) Sandra Gerges (612561) Sherif Samwaiel (218729) Sylvia Mekhail (604292)	Sherif Samwaiel (218729)	August 26, 2011
Total Health #119	3251 Sheppard Avenue East Scarborough, ON	Natsherri Inc.	Sherif Gerges (205836) Masoud Amidi-Mazaheri (609114) Sherif Samwaiel (218729) Hany Kot (216513)	Sherif Samwaiel (218729)	August 26, 2011
Vanguard Drug Mart	565 College Street Toronto, ON	Van-To Pharmacy Limited	To Ha (88919)	To Ha (88919)	August 16, 2011
Vaughan Neighbourhood Pharmacy	68-3175 Rutherford Road Vaughan, ON	1695781 Ontario Corporation	Thi (Tammy) Minh Thu Mai (213249) Khanh Cong Bui	Thi (Tammy) Minh Thu Mai (213249)	August 18, 2008
Warden Pharmacy	119-30 Gibson Drive Markham, ON	AS169988 Consultants Inc.	Xiao Ning (Sean) Xu (609448) Wu Ying Peng	Xiao Ning (Sean) Xu (609448)	September 25, 2017
Wellmart Pharmacy	347 Spadina Avenue Toronto, ON	1466409 Ontario Inc.	Can Minh Le (201024)	Can Minh Le (201024)	August 21, 2008
West End Medical Pharmacy	2209 Bloor Street West Toronto, ON	St. Barbara's Pharmacy Ltd	Omelan Chabursky (6068)	Natalya Ivasiv (220077)	August 26, 2014
Westview Pharmacy	2115 Finch Avenue West Toronto, ON	A and 2M Drugs Limited	Amany Hanna (214829) Ihab Yacoub (214493) Amir Besada (96326)	Amany Hanna (214829)	March 24, 2010
Wilson Medical Pharmacy	554 Main Street East Hamilton, ON	Safaa Pharmacy Inc.	Souren Agemian (922) Safaa Eskander (116661) Ayman Mikhael (111279)	Safaa Eskander (116661)	February 22, 2012

The following is a list of every pharmacy operator that has received notice from the EO of Ontario Public Drug Programs that it may have its billing privileges revoked, its right to receive payment suspended, and its HNS Subscription Agreement terminated, because the EO has reasonable grounds to believe that the operator has submitted unsupported and invalid claims for payment under the Ontario Public Drug Programs.

Pharmacy Name	Address	Corporation	Officers/Directors/Shareholders (OCP# if applicable)	Designated Manager	Date
Deer Ridge Pharmacy	B-4281 King Street East Kitchener, ON	2575328 Ontario Limited	Nhu (Vivian) Huynh (220245) Vu Nguyen (613881)	Vu Nguyen (613881)	June 3, 2024

Archived Executive Officer Communications

Historical archive of individual Executive Officer Communications published prior 2015